CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 120 enrolled
Drug / intervention
Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dosedrug
Likely dose
Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dosefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04862962
NCT04862962N/ACompleted
CompareCT.gov

Retrospective Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin / Ezetimibe as a Treatment for Patients With Dyslipidaemia in Usual Medical Practice.

Laboratorios Silanes S.A. de C.V.·observational·Posted Apr 28, 2021·Updated Mar 2, 2022

In Brief

An observational study evaluating Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose for Dyslipidemias. Completed, enrolled 120 participants across 1 site.

Detailed Summary

Retrospective, analytical, longitudinal, multicenter study to evaluate the safety of the fixed-dose combination of rosuvastatin / ezetimibe as treatment for patients with dyslipidemia in routine medical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemias
CountriesMexico
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedApr 28, 2021
Enrollment StartSep 30, 2021
Primary CompletionJan 15, 2022
Study CompletionFeb 15, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.2 years ago

Interventions

Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dosedrug

Oral Tablets 10 mg/10 mg or 20 mg/10 mg